June 28 (Reuters) - Pfizer Inc and Moderna Inc
said on Tuesday they will be ready with COVID-19
vaccines designed to combat the BA.1 Omicron variant that was
dominant last winter earlier than those designed to target
currently dominant subvariants.
Moderna said it would be ready with a "couple of hundred
million" of bivalent vaccines designed to combat BA.1 by
September, but it would be late October or early November if the
vaccine maker needed to design a vaccine to combat the currently
dominant BA.4 and BA.5 subvariants.
Pfizer said it has a significant amount of BA.1 vaccine
produced already and is preparing to produce a large amount of
vaccine against BA.4 and BA.5 subvariants. It said either
vaccine could be ready for an early October rollout.
(Reporting by Leroy Leo in Bengaluru; Editing by Leslie Adler)